Venous Thromboembolism (VTE) Market 2021 Statistical Analysis, Key Segments, Benefits and Opportunity and Forecast 2030

Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE)

Venous thromboembolism (VTE) is a leading cause of death and disability worldwide, according to the International Society on Thrombosis and Hemostasis, Inc. Venous thromboembolism affects about 10 million people each year. The formation of blood clots in veins is referred to as VTE. Deep vein thrombosis refers to a clot in a deep vein (usually in the leg), whereas pulmonary embolism refers to a clot in the lungs.

In the United States, between 100,000 and 300,000 VTE-related deaths are reported each year (International Society on Thrombosis and Hemostasis, Inc.). In Europe, the figure is much higher, at 544,000 deaths per year. Furthermore, up to 60% of VTE cases are believed to occur during or after hospitalisation. This easily avoidable health problem is frequently overlooked.

Heparin has long been considered the gold standard in the treatment of Venous Thromboembolism (VTE) Market. Rivaroxaban was found to be more effective than aspirin in reducing the risk of recurrent events in patients with venous thromboembolism in a recent study published in the New England Journal of Medicine. Compression stockings and intermittent pneumatic compression devices are two devices used to treat VTE. Tissue plasminogen activator is used as part of thrombolytic therapy.

In March 2017, the APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) trial found that using betrixaban after parenteral prophylaxis with enoxaparin reduces the risk of Venous Thromboembolism (VTE) Market in patients discharged from the hospital. There are currently no anticoagulants approved for long-term use in patients who have been discharged from the hospital or who are at high risk of VTE. This treatment approach has the potential to benefit those patients and contribute to the global venous thromboembolism market's growth.

According to a 2014 article published by the World Thrombosis Day steering committee, the incidence rate of VTE in North America, Western Europe, Australia, and southern Latin America (Argentina) was in the range of 0.75-2.69 per 1,000 people, rising to 2-7 per 1,000 people in people aged 70 and up. Furthermore, according to the findings of the study, global awareness of Venous Thromboembolism (VTE) Market is very low. Furthermore, with the exception of North America and Europe, the condition is largely undocumented. In March 2017, Daiichi Sankyo Company, Limited launched a large-scale clinical registry for cancer-VTE patients in Japan. This facility would enrol and track 10,000 cancer patients for a year in order to achieve the following goals.

Comments

Popular posts from this blog

Endometrial Ablation Market Analysis, Industry Scope, Global Opportunity Analysis and Forecast Till 2027

Intravenous Fluid Therapy is the Fastest Growing Segment Fueling the Growth of Intravenous Solutions Market

Artificial Intelligence And Machine Learning Are Fueling Growth Of Assessment Services Market